Arcpoint Labs

For the astute investor navigating the burgeoning health and wellness landscape, the critical question often revolves around identifying a franchise opportunity that not only promises robust growth but also delivers essential services within a stable, high-demand market. The diagnostic testing industry, a foundational pillar of modern healthcare, presents precisely such an arena, yet it is often characterized by either impersonal large corporations or smaller, under-resourced independent labs. This inherent market inefficiency, marked by a lack of personalized service from national giants and limited competitive buying power for local entities, formed the precise problem statement that Felix Mirando sought to address when he founded ARCpoint Labs in 1998 in Greenville, South Carolina. Initially concentrating on drug and alcohol testing for small and medium-sized businesses, Mirando’s vision for ARCpoint Labs was to ingeniously combine the personalized touch of local ownership with the formidable technological capabilities and national purchasing power typically reserved for much larger organizations. This strategic positioning allowed ARCpoint Labs to carve out a distinct and valuable niche, evolving over two decades to offer a comprehensive suite of diagnostic testing services catering to both businesses and individuals. Today, ARCpoint Labs stands as a significant player in the direct-access lab testing sector, having launched its franchising program in 2006 and rapidly expanding its footprint to over 100 locations within its first decade of franchising. As of the 2024 Franchise Disclosure Document data, there are 138 franchised ARCpoint Labs locations operating across the United States, with other reports indicating 117 units as of December 2022, and a total of 143 units comprising 138 open franchises and 5 corporate locations. By August 2024, the company proudly boasted over 130 locations nationally, demonstrating a consistent growth trajectory in 27 states, with a notable concentration of 84 franchises located within the Southern region. This extensive network, coupled with its recent strategic integration into CRESSO BRANDS, LLC alongside Any Lab Test Now in August 2024, has positioned ARCpoint Labs as an integral component of the largest direct-access lab testing group in the United States, a testament to its market significance and growth potential. The broader medical laboratories market, within which ARCpoint Labs operates, is projected to reach an impressive $300,299.68 million by 2030, exhibiting a robust Compound Annual Growth Rate (CAGR) of 5.10% over the forecast period of 2024-2030, underscoring the immense total addressable market and why this brand represents a compelling franchise opportunity for discerning investors seeking to capitalize on a critical and expanding sector.

The industry landscape for diagnostic testing, encompassing medical laboratories and clinical laboratory services, presents a compelling narrative of sustained expansion and high demand, making it an attractive sector for franchise investment. The global clinical laboratory services market alone was valued at USD 256.9 billion in 2024 and is estimated to reach USD 391.8 billion by 2033, exhibiting a strong Compound Annual Growth Rate (CAGR) of 4.80% during the 2025-2033 period. North America plays a dominant role in this growth, holding over 39.2% market share in 2024 for clinical lab services, with the United States accounting for a substantial 88.50% of the North American market. This robust market environment is fueled by several key consumer trends and secular tailwinds that directly benefit the ARCpoint Labs franchise model. Increasing health consciousness among the general populace, a greater emphasis on preventative care, and the growing demand for convenient, direct-access testing services are significant drivers. Furthermore, the imperative for employer compliance with drug screening regulations and the expansion of corporate wellness programs contribute substantially to the demand for ARCpoint Labs’ services. The company’s strategic expansion into Employee Assistance Programs (EAP) and Wellness Panels in 2022 directly addresses these evolving needs, diversifying its revenue streams and strengthening its market relevance. The 2023 affiliation with a nationwide MD group to facilitate after-care based on testing results further integrates ARCpoint Labs into the broader healthcare ecosystem, enhancing its value proposition to consumers seeking holistic health solutions. The industry attracts franchise investment due to its essential nature, which often translates into resilience against economic fluctuations, and the non-discretionary spending associated with health and compliance requirements. While the market for diagnostic testing can appear fragmented, the recent acquisition of ARCpoint Labs by CRESSO BRANDS, LLC, forming the largest direct-access lab testing group in the U.S., signals a strategic consolidation that creates a powerful competitive entity. Macro forces such as stringent regulatory compliance for occupational health services, the increasing prevalence of chronic diseases requiring regular monitoring, and a patient population empowered by greater medical literacy all contribute to a fertile ground for growth and opportunity for the ARCpoint Labs franchise system.

Investing in an ARCpoint Labs franchise requires a clear understanding of the financial commitments involved, positioning it as a mid-tier opportunity within the franchise spectrum. The standard initial franchise fee is set at $54,500, a figure that has seen an adjustment from $45,000 in 2015, when multi-territory discounts were also available, offering fees of $45,000, $40,000, and $35,000 for three territories respectively. A specific veteran discount of $5,000 off the initial franchise fee is also provided, demonstrating support for military service members transitioning into business ownership. The total initial investment required to establish an ARCpoint Labs franchise spans a considerable range, reflecting variations in real estate costs, market conditions, and specific build-out requirements. Recent estimates include a range of $200,800 to $361,720 based on 2024 FDD data, with other figures citing $199,000 to $380,000 as of October 2025, and $200,000 to $365,000 as of 2026, while a detailed breakdown suggests an initial investment from $165,700 to $310,420, with an initial investment starting at $175,300 also mentioned. This comprehensive investment covers a multitude of essential expenses, including the initial training fee of $7,500, travel and living expenses during training estimated at $1,000-$5,425 per person, and significant allocations for rent or real estate improvements ranging from $20,000-$80,000. Further costs encompass office furniture, fixtures, and equipment ($500-$8,000), décor items ($2,000-$6,000), computer equipment, software, and telephone systems ($2,550-$5,500), and specialized testing equipment ($1,500-$4,000). Operational necessities such as insurance ($4,500-$24,495), signage ($2,000-$7,000), legal and accounting fees ($4,500-$9,000), initial inventory ($10,750-$22,500), business licenses and permits ($100-$2,000), and dues/subscriptions/memberships ($300-$2,500) are also factored into the total initial outlay. Prospective franchisees are required to possess a minimum of $100,000 in liquid capital, with a working capital range of $54,000 to $72,000, and a minimum net worth of $400,000, underscoring the financial readiness expected from candidates. The cash investment is specifically stated as $97,500. Beyond the initial investment, ongoing fees are a critical component of the total cost of ownership for an ARCpoint Labs franchise. Franchisees pay a royalty fee of 7% of gross revenue per month, with a minimum payment threshold of $350 per month. Additionally, a contribution to the National Marketing Fund is required, currently set at 2% of gross revenue per month, though the franchisor reserves the right to increase this to 3%. There is also a local advertising requirement, stipulating $15,000 for the first 12 months of lab operations, followed by the greater of 3% of gross sales or $9,000 per 12 months thereafter. An Advertising Cooperative/Multi-Area Marketing fee of 1% to 3% of gross revenue may be implemented in specific market areas. Further ongoing fees include a doctor referral fee of up to $2 per requisition and/or injection, and a technology fee of $300 starting 60 days after signing the Franchise Agreement until lab operations commence, increasing to $450 per month thereafter. These combined ongoing fees, particularly the 7% royalty and 2% national marketing contribution, represent a structured financial commitment, typical for service-based franchises that rely on centralized support, brand building, and continuous technological advancements to maintain a competitive edge for ARCpoint Labs. The parent company, ARCpoint Franchise Group, and its integration into CRESSO BRANDS, LLC, provide robust corporate backing and strategic advantages, including potential for favorable vendor agreements and national account opportunities.

The operational framework and comprehensive support system provided by ARCpoint Labs are meticulously designed to guide franchisees through every stage of business development and daily management, fostering a model that prioritizes both efficiency and compliance within the diagnostic testing sector. For a franchisee, daily operations at an ARCpoint Labs location typically involve managing a diverse array of diagnostic testing services, including drug and alcohol screening, clinical diagnostic panels, judicial system support services, Employee Assistance Programs (EAP), and various wellness panels. This necessitates a structured approach to client intake, precise sample collection procedures, efficient coordination with laboratory partners for processing, and the timely, secure delivery of results to individuals and businesses. The staffing requirements for an ARCpoint Labs center generally include trained personnel capable of performing sample collections, such as phlebotomists or medical assistants, alongside administrative staff to manage appointments, customer inquiries, and data entry. The labor model is therefore highly influenced by the volume of testing requests and the complexity of the services offered, requiring a team that is both medically competent and customer-service oriented. While the core model is based on "brick and mortar" physical lab locations, the company demonstrated flexibility during the COVID-19 pandemic by providing both in-lab and mobile site testing for illness and antibodies, suggesting an adaptable service delivery capability. The initial training program for ARCpoint Labs franchisees is extensive, comprising a total of 91 hours, with 75 hours dedicated to intensive classroom instruction and an additional 16 hours of practical, on-the-job training. This program was significantly overhauled in 2017 under new leadership to provide franchisees with enhanced tools, resources, and support, ensuring they are well-equipped to navigate the complexities of the diagnostic testing industry. Beyond initial training, the corporate support structure for ARCpoint Labs franchisees is robust and ongoing. It includes access to an Online Learn Upon Training platform for continuous education, a New Owner Shadowing Program for practical insights, and a dedicated ARCpoint Sales Program to assist with client acquisition. Franchisees also receive comprehensive Lab Buildout requirements and examples, a Weekly Newsletter for timely updates, and participate in Monthly Owner Update Calls. Regular Educational Webinars are conducted to keep franchisees abreast of industry developments, compliancy requirements, and clinical education. Crucially, franchisees gain access to ARCpoint's national network and resources, which are vital for business growth, including preferred vendor relationships and aggregated buying power. While franchisees operate within a defined territory, it is important to note that exclusivity is not granted, and the franchisor explicitly reserves the right to operate its own "brick and mortar" businesses outside a franchisee's designated territory. Although specific multi-unit requirements are not detailed, the historical availability of multi-territory discounts suggests that ARCpoint Labs encourages growth through multiple units for qualified operators. The comprehensive nature of the training and support, coupled with the critical service provided, generally aligns with an owner-operator model or one with highly engaged, professional management overseeing daily operations.

For prospective investors evaluating an ARCpoint Labs franchise, the critical question of financial performance is paramount, even in the absence of Item 19 financial performance data in the current Franchise Disclosure Document. It is important to clearly state that Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document, meaning specific average revenue, median revenue, or profit margins are not formally presented by the franchisor. However, an analysis of publicly available revenue data, industry benchmarks, and the brand's growth trajectory can provide valuable insights into potential unit-level performance for an ARCpoint Labs location. One source reports an average gross revenue of $281,576 for ARCpoint Labs franchises, though it notes this figure "significantly underperforms the sub-sector average of $700,908." Conversely, another report indicates that top-performing ARCpoint Labs locations achieve an average of $544,193 in gross sales, highlighting a considerable variability in financial outcomes across the network. This disparity suggests that factors such as franchisee operational excellence, market demographics, local competitive dynamics, and adherence to the ARCpoint Sales Program significantly influence individual unit performance. The broader industry revenue benchmarks for medical laboratories are substantial, with the market projected to reach $300,299.68 million by 2030, and the global clinical laboratory services market valued at USD 256.9 billion in 2024, indicating a vast market with ample revenue potential for well-managed units. ARCpoint Labs’ strategic position as part of CRESSO BRANDS, LLC, forming the largest direct-access lab testing group in the U.S., is a significant competitive advantage. This consolidation likely provides enhanced negotiating power with suppliers, access to advanced technology platforms, and opportunities for national account acquisition, all of which could positively impact unit-level gross revenue and, by extension, potential owner earnings for ARCpoint Labs franchisees. The consistent unit count growth trajectory further signals positive momentum and franchisee confidence in the ARCpoint Labs model. The network launched its franchising program in 2006, grew to 100 locations within a decade, expanded to 117 units by December 2022, and reached 138 franchised units in the USA by 2024 FDD data, with over 130 locations reported by August 2024. This steady expansion, particularly the addition of 21 franchised units between 2022 and 2024, suggests that the underlying unit economics are sufficiently attractive to drive continued investment and growth. Furthermore, the company's proactive expansion of its product lines, including the "Four Pillars" approach (direct-to-consumer, judicial, and clinical programs), and the introduction of new services like Employee Assistance Programs (EAP) and Wellness Panels in 2022, are designed to diversify revenue streams and increase the average transaction value and customer lifetime value for ARCpoint Labs franchisees. The innovative affiliation with a nationwide MD group in 2023 for after-care services also positions ARCpoint Labs to capture additional revenue opportunities by providing a more integrated healthcare solution, all of which contribute positively to the potential for robust unit-level performance and strong financial returns within the ARCpoint Labs system.

The growth trajectory of ARCpoint Labs demonstrates a consistent and strategic expansion, underpinned by a series of corporate developments designed to enhance its market position and competitive advantages. Since launching its franchising program in 2006, ARCpoint Labs has achieved significant milestones, growing to 100 locations within its first decade of franchising. This momentum has continued, with the network reaching 117 units by December 2022, and further expanding to 138 franchised locations in the USA as reported in the 2024 FDD data, with over 130 locations across the country by August 2024. This represents a net addition of 21 franchised units in a span of just two years, indicating a healthy rate of expansion and sustained franchisee interest in the ARCpoint Labs brand. Several key corporate developments have shaped this growth. In 2017, the company initiated "ARCpoint 2.0" under new leadership, a strategic overhaul focusing on new market opportunities and transforming the company into a national network. This initiative led to a significant expansion of product lines between 2017 and 2019, developing the "Four Pillars" approach to diagnostic testing, which introduced new revenue streams through direct-to-consumer, judicial, and clinical programs. A pivotal moment for ARCpoint Labs occurred in 2020 when the company played a significant role during the COVID-19 pandemic, providing essential in-lab and mobile site testing for illness and antibodies, showcasing its operational agility and capacity to respond to urgent public health needs. Further growth was driven in 2022 with the introduction of new services, including Employee Assistance Programs (EAP) and Wellness Panels, diversifying the brand's offerings and tapping into growing health and corporate wellness trends. In 2023, ARCpoint Labs added an innovative affiliation with a nationwide MD group to assist patients with after-care based on testing results, facilitating easier access to comprehensive healthcare solutions. The most transformative development came in August 2024, when ARCpoint Labs joined CRESSO BRANDS,